Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maja de Jonge

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Multitarget tyrosine kinase inhibition: [and the winner is...]Jaap Verweij, Maja de Jonge
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2005
The epothilone dilemmaMaja de Jonge, Jaap Verweij
European Journal of Cancer (Oxford, England : 1990)|February 15, 2008
QTc prolongation and/or oncology drug development: who's in danger?Maja de Jonge, Jaap Verweij
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
The multi-institutional phase I study: disadvantages without advantages?Jaap Verweij, Ferry Eskens, Maja de Jonge
Molecular Oncology|March 6, 2012
Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial designJaap Verweij, Maja de Jonge, Ferry Eskens, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2010
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinibEmma Guttman-Yassky, Alain Mita, Maja De Jonge, et al.
Cancer Chemotherapy and Pharmacology|November 30, 2023
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human studyCarla Biesdorf, Xiaowen Guan, Satya R Siddani, et al.
Cancer Chemotherapy and Pharmacology|June 28, 2011
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitorPaul Hamberg, Margaret M Woo, Lin-Chi Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2011
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumorsJohanna C Bendell, Jordi Rodon, Howard A Burris, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2022
First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumoursPatrick Schöffski, Ahmad Awada, Anne-Marie de la Bigne, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Multitarget tyrosine kinase inhibition: [and the winner is...]Jaap Verweij, Maja de Jonge
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2005
The epothilone dilemmaMaja de Jonge, Jaap Verweij
European Journal of Cancer (Oxford, England : 1990)|February 15, 2008
QTc prolongation and/or oncology drug development: who's in danger?Maja de Jonge, Jaap Verweij
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
The multi-institutional phase I study: disadvantages without advantages?Jaap Verweij, Ferry Eskens, Maja de Jonge
Molecular Oncology|March 6, 2012
Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial designJaap Verweij, Maja de Jonge, Ferry Eskens, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2010
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinibEmma Guttman-Yassky, Alain Mita, Maja De Jonge, et al.
Cancer Chemotherapy and Pharmacology|November 30, 2023
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human studyCarla Biesdorf, Xiaowen Guan, Satya R Siddani, et al.
Cancer Chemotherapy and Pharmacology|June 28, 2011
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitorPaul Hamberg, Margaret M Woo, Lin-Chi Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2011
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumorsJohanna C Bendell, Jordi Rodon, Howard A Burris, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2022
First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumoursPatrick Schöffski, Ahmad Awada, Anne-Marie de la Bigne, et al.
Pageof 3